CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| AEPI07N1 | COG | Genetic Susceptibility Factors in the Etiology of Neuroblastoma also known as Neuroblastoma Epidemiology in North America (NENA): A Groupwide Non-Therapeutic Study | Pediatric CIRB | Completed |
| ALTE16C1 | COG | Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma | Pediatric CIRB | Available to Open |
| ADVL1414 | COG | A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS Tumors | Pediatric CIRB | Available to Open |
| AHOD2131 | COG | A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma | Pediatric CIRB | Available to Open |
| AAML0431 | COG | The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| ARAR0331 | COG | Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| ANHL1522 | COG | A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) | Pediatric CIRB | Available to Open |
| ACCL0631 | COG | Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children with High Risk Acute Lymphoblastic Leukemia (ALL): A Group-wide Non-Therapeutic Study | Pediatric CIRB | Completed |
| ANHL2121 | COG | Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis | Pediatric CIRB | Available to Open |
| AHOD0831 | COG | A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study | Pediatric CIRB | Completed |